Gilbert Halley E, an insider at Arcutis Biotherapeutics Inc (ARQT), acquired 38,655 shares of the company on November 19, 2025, at a price of $7.51 per share. The total value of this transaction amounted to approximately $290,000.
Following this purchase, Halley holds a total of 38,655 shares in Arcutis Biotherapeutics, a biotechnology firm based in Westlake Village, California. The company is focused on developing and commercializing treatments for dermatological diseases, with its lead product, ZORYVE, indicated for plaque psoriasis and atopic dermatitis. Arcutis Biotherapeutics has a market capitalization of $3.4 billion and employs 342 full-time staff.
Insider transactions, such as this one, can offer insights into the confidence executives have in their company's future. However, it is essential for investors to consider insider activity within a broader context, examining patterns across multiple insiders and time periods rather than relying on isolated transactions.
Arcutis is set to report its upcoming earnings on August 4, 2026, with an estimated EPS of $0.06 and revenue of $113.6 million. This follows a prior estimate for May 4, 2026, where EPS is projected at -$0.01 with revenue of $100.2 million.
The transparency provided by these insider transactions must be reported to the SEC, contributing to a clearer understanding of executive sentiment regarding stock performance.